RCUSArcus Biosciences, Inc.
Pharmaceutical Preparations
- Revenue
- $33M
- 35% YoY
- Operating margin
- -1169.7%
- 81% YoY
- EBITDA
- −$376M
- 18% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$49M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired182% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $383M | $38M | $37M | $51M | $33M | 35% |
| Operating income | $54M | −$280M | −$340M | −$330M | −$386M | 17% |
| Net income | $53M | −$267M | −$307M | −$283M | −$353M | 25% |
| Operating cash flow | −$256M | $438M | −$306M | −$170M | −$482M | 184% |
| Capex | $26M | $6M | $24M | $6M | $2M | 67% |
| Stock-based comp | $55M | $65M | $73M | $76M | $60M | 21% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $1M · 3
- Net
- −$1M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $10M | $18M | 90 | 88 |
| FY2024 | $7M | $5M | 147 | 95 |
| FY2023 | $10M | $7M | 194 | 94 |
| FY2022 | $9M | −$2M | 205 | 88 |
| FY2021 | $9M | $15M | 401 | 118 |